U.S. Communications Stock News

Why Goodyear’s latest earnings matter for shareholders Goodyear Tire & Rubber (GT) just reported fourth quarter and full year 2025 results, with stronger quarterly profit but a full year net loss, giving investors mixed signals on the stock’s recent performance. See our latest analysis for Goodyear Tire & Rubber. The mixed earnings story is also showing up in the trading data, with the 90 day share price return of 9.83% pointing to improving momentum. In contrast, the 1 year total shareholder...

Verra Mobility (VRRM) drew fresh investor attention after securing a 10 year contract worth roughly US$160 million with Hawaii’s Department of Transportation to expand its automated red light and speed enforcement program statewide. See our latest analysis for Verra Mobility. The Hawaii contract follows another large win with New York City earlier in February. Together, these updates contrast with a softer share price picture, with a 30-day share price return of an 11.16% decline, a...

Gaming and Leisure Properties, Inc. recently reported record 2025 results, with revenue rising to US$1.59 billion and net income reaching US$825.11 million, while also declaring a US$0.78 per-share dividend for the first quarter of 2026. Alongside these earnings, the completion of the US$700 million Bally’s Lincoln acquisition and a US$2.6 billion committed development pipeline highlight how GLPI is expanding its casino real estate footprint while keeping leverage below its internal...

If you are wondering whether DocuSign's current share price reflects its true worth, you are not alone. This article will help you frame that question clearly. With the stock closing at US$44.48 and returns of a 0.8% decline over 7 days, a 22.6% decline over 30 days, a 31.4% decline year to date and a 47.0% decline over 1 year, many investors are reassessing what a fair price looks like for DocuSign. Recent coverage has focused on how DocuSign is repositioning itself within the broader...

Paychex Director Joseph Doody recently acquired additional shares of NasdaqGS:PAYX, signaling increased personal exposure to the company. The insider purchase comes as Paychex shares trade at $91.24 following a 16.0% decline year to date. This transaction adds a fresh data point for investors watching insider activity at Paychex. For investors tracking Paychex, the timing of this insider buying stands out against a weaker recent share performance. The stock is at $91.24, with a 7 day return...

If you are wondering whether CRA International's current share price reflects its real value, you are not alone. The stock has a mix of recent returns that raises fair questions about what it is truly worth. At a last close of US$166.60, CRA International has returned 7.3% over the past week, after a 20.3% decline over 30 days and year to date and 1 year returns of 16.9% and 16.2% declines. The 3 year and 5 year returns sit at 38.1% and 221.5% respectively. These moves come against a...

Nu Holdings (NYSE:NU) has outlined a global expansion plan that includes significant investment in new international offices. The company has acquired AI firm Hyperplane to deepen its data and machine learning capabilities across its product suite. Nu has secured a conditional U.S. national bank charter, opening the door to offering regulated banking services in the United States. The company has also entered a partnership with the Mercedes AMG PETRONAS F1 Team as part of its global brand...

Vestis (VSTS) moved after releasing first quarter 2026 results, which showed lower sales and a net loss. The company also reaffirmed its full year guidance for revenue, projecting results between flat and a 2% decline. See our latest analysis for Vestis. The earnings release and reaffirmed guidance seem to have shifted sentiment in the short term, with a 1-day share price return of 3.91% and a 30-day share price return of 16.50% at a latest share price of $7.98. However, the 1-year total...

Vertex Pharmaceuticals (VRTX) drew fresh attention after reporting full year 2025 results, with revenue of US$12.0b and net income of US$3.95b, alongside guidance highlighting contributions from Casgevy and Journavx. See our latest analysis for Vertex Pharmaceuticals. That backdrop has come with a mixed price move, with a 12.48% 90 day share price return and a modest 1.81% 30 day share price return, while the 1 year total shareholder return of 1.52% decline contrasts with a 65.95% gain over...

Earlier in February 2026, Albemarle said it had idled the last operating train at its Kemerton lithium hydroxide plant in Western Australia, recorded US$245.60 million of long‑lived asset impairments for the December 2025 quarter, and reported a quarterly net loss despite higher sales. At the same time, Albemarle guided to 2026 net sales of US$5.70 billion to US$6.00 billion with flat volumes, while shifting Kemerton into care and maintenance but planning to meet lithium hydroxide demand...

Voya Financial (VOYA) has launched a new fixed income offering of senior, unsecured fixed rate notes, shortly after filing an omnibus shelf registration that covers debt, equity, preferred stock, depositary shares, warrants, and units. See our latest analysis for Voya Financial. Voya’s new notes come after a period where momentum has softened slightly in the short term, with a 30 day share price return of a 1.83% decline. The 1 year total shareholder return of 6.56% and 5 year total...

JPMorgan Chase (NYSE:JPM) confirmed it closed bank accounts held by former President Donald Trump and his businesses after the January 6, 2021 US Capitol events. New court filings in an ongoing lawsuit allege the closures were politically motivated, while the bank cites reputational risk considerations. The case brings fresh attention to how one of the largest US banks handles high profile clients when legal, political and reputational issues intersect. For you as an investor, this puts a...

If you are wondering whether TopBuild is still good value after a strong run, this article will walk through what the current share price could mean for you as an investor. The stock closed at US$518.92, with returns of 6.3% over the last 30 days, 20.3% year to date and 70.8% over 1 year. The 7 day return of a 5.8% decline may have some investors reassessing the balance between opportunity and risk. Recent coverage has focused on TopBuild as a key player in building products and installation...

If you are wondering whether Regeneron Pharmaceuticals is still priced fairly after a strong multi year run, or if the market is missing something in plain sight, this article will help you weigh what you are really paying for. The stock most recently closed at US$779.67, with returns of 3.5% over 30 days and 74.2% over 5 years, so recent moves and longer term performance give mixed signals on how the market is pricing its potential and risks. Recent headlines around Regeneron have focused...

Liberty Global Ltd. has reported its full-year 2025 results, with sales rising to US$4,878.5 million from US$4,341.9 million, but swinging from a net income of US$1.59 billion to a very large net loss of US$7.14 billion and a basic loss per share from continuing operations of US$20.86. The combination of higher revenue and a very large reported loss raises questions about cost structure, one-off charges, and how resilient the business model really is. We’ll now consider how this sharp move...

In February 2026, Airbnb reported fourth-quarter 2025 revenue of US$2,778 million and net income of US$341 million, with full-year 2025 revenue of US$12.24 billion and net income of US$2.51 billion, alongside completing share repurchases totaling US$6.47 billion across two programs. The company paired these results with a new US$2.32 billion shelf registration for employee share offerings and highlighted product initiatives like Reserve Now, Pay Later and transparent pricing as key drivers...

Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with a wider net loss and ambitious 2026 sales guidance. See our latest analysis for Insmed. Insmed’s recent earnings and guidance have come alongside a sharp move in the share price, with a 10.86% 7 day share price return and 5.57% 30 day share price return partly offsetting a 21.10% 90 day share price decline. The 1 year total shareholder...

If you are wondering whether CONMED's current share price reflects its true worth, this article walks through the key signals that matter for value focused investors. The stock last closed at US$45.14, with a recent return of 8.0% over 7 days and 8.4% over 30 days, set against an 11.4% return year to date and a 25.4% decline over the past year. These moves sit against a backdrop of ongoing interest in medical devices and surgical technologies. Investors are watching how companies like CONMED...

If you are wondering whether Qiagen's current share price offers fair value or a potential gap to fundamentals, you are in the right place. The stock last closed at US$48.57, with returns of 22.1% over 1 year and 2.1% year to date. Over the past week and 30 days it saw declines of 3.7% and 12.7% respectively, which may have changed how the market views its risk and opportunity. Recent news flow around Qiagen has mainly focused on its role in molecular diagnostics and life sciences tools,...

What Ascendis Pharma’s Recent Trading Signals Tell You Ascendis Pharma (NasdaqGS:ASND) has drawn attention after recent trading left the share price around $225, with a modest gain over the past week but a small decline over the past month. For context, the stock shows a positive total return over the past 3 months and past year. Longer multiyear returns and current fundamentals such as revenue, net income, and valuation metrics shape how some investors are reassessing the risk and reward...

American Water Works Company (NYSE:AWK) and Essential Utilities shareholders have overwhelmingly approved an all stock, tax free merger. The combined company will operate under the American Water name and is expected to become the largest regulated water and wastewater utility in the United States. The merger is targeted to close by the end of Q1 2027, subject to regulatory approvals across the involved jurisdictions. For you as an investor following NYSE:AWK, this vote is a key corporate...

If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing attention from investors focused on value. The share price has seen a 12.9% decline over the last 7 days, 20.8% over 30 days, 8.8% year to date and 45.2% over 1 year, even though the 3 year and 5 year returns sit at 63.4% and 38.4% respectively. Recent coverage has largely centered on ongoing developments in its pharmaceutical and...

Quantum Computing Inc. (NasdaqCM:QUBT) has acquired Luminar Semiconductor, adding integrated photonics capabilities to its quantum computing portfolio. The company is shifting its growth focus toward integrated photonics based architectures for quantum information processing. Quantum Computing Inc. is also expanding its contracts with the United States Department of Defense, increasing its exposure to government and defense related work. For you as an investor, this move puts Quantum...

The Trump administration’s move to impose a 15% global tariff for up to 150 days immediately put Flex (FLEX) in focus, as its globally integrated supply chain makes trade policy shifts especially relevant for investors. See our latest analysis for Flex. That tariff-related 3.4% share price drop came against a much stronger backdrop for Flex, with a 90 day share price return of 15.33% and a 1 year total shareholder return of 62.74%. This suggests momentum has been firmly positive despite short...